| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Biotinyl tyramide is a substrate for horseradish peroxidase (HRP) enzyme. In the presence of H2O2, HRP catalyzes the conversion of biotinyl tyramide to a reactive radical species that covalently binds to nearby proteins. This process, known as tyramide signal amplification (TSA), dramatically increases detection sensitivity. The compound binds to viral RNA and DNA, which are involved in polymerase chain reactions. It is used to enhance AR immunoreactivity in the rat brain, including regions such as the medial PFC and orbitofrontal cortex.
|
|---|---|
| ln Vitro |
In vitro, Biotinyl tyramide is used as a reagent to amplify immunohistochemical signals and in situ hybridization protocols. It serves as a substrate for HRP, enabling signal amplification through TSA. The compound has been used in detecting procalcitonin, aiding in distinguishing bacterial infections. Biotinyl tyramide binds to viral RNA and DNA in polymerase chain reactions. It is used as a model system for biological processes. The compound enhances electrochemical immunosensors.
|
| ln Vivo |
In vivo, Biotinyl tyramide has been used to dramatically increase AR immunoreactivity in the rat brain, including critical regions of the prefrontal cortex such as the medial PFC and orbitofrontal cortex. The compound is used in tissue-based detection systems. Its TSA-based signal amplification enables detection of low-abundance targets in tissues. Biotinyl tyramide is used in various in vivo detection applications including immunohistochemistry and in situ hybridization. Further in vivo studies have evaluated its utility in various detection systems.
|
| Enzyme Assay |
In vitro enzyme assays for Biotinyl tyramide involve HRP enzyme activity measurement. HRP catalyzes the conversion of biotinyl tyramide to reactive species in the presence of H2O2. Enzyme activity is assessed by monitoring the deposition of biotinylated products on solid surfaces. Signal amplification efficiency is quantified by comparing signals with and without TSA. Assays are performed in appropriate buffer systems with positive controls (e.g., known HRP substrates). The compound’s utility as a TSA reagent is confirmed through these assays.
|
| Cell Assay |
In vitro cell-based assays for Biotinyl tyramide are conducted in tissue sections or cell preparations. Cells or tissues are fixed and processed for immunohistochemistry or in situ hybridization. Biotinyl tyramide is applied in the presence of HRP and H2O2, and signal amplification is assessed by chromogenic or fluorescence detection. Target detection sensitivity is compared with and without TSA. Experiments are performed with appropriate positive and negative controls. The compound’s utility in enhancing detection of low-abundance targets is evaluated.
|
| Animal Protocol |
In vivo animal studies for Biotinyl tyramide are conducted in rodent models for tissue detection applications. Animals are perfused and brain or other tissues are collected and sectioned. Biotinyl tyramide-based TSA is applied to tissue sections to enhance immunoreactivity. AR or other target protein signals are detected by immunohistochemistry. Signal intensity is compared with and without TSA. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Biotinyl tyramide (MW 363.5 g/mol, C18H25N3O3S) is a biotin derivative. The compound is soluble in DMSO and other organic solvents. It is stable under recommended storage conditions. Biotinyl tyramide is used as a reagent for signal amplification. Its biotin moiety enables binding to streptavidin or avidin for detection. The compound is typically used in solution for immunohistochemistry and in situ hybridization applications. Pharmacokinetic properties are not typically characterized as it is a detection reagent.
|
| Toxicity/Toxicokinetics |
Biotinyl tyramide is generally considered safe as a laboratory reagent. The compound is used in research applications for signal amplification. No significant adverse effects have been reported at research-use concentrations. The compound is intended for research use only. Standard laboratory safety practices should be employed when handling this compound. Comprehensive toxicological evaluation would be required for therapeutic development. The compound is not intended for human use.
|
| References |
|
| Additional Infomation |
Biotinyl tyramide is a biotin derivative used for tyramide signal amplification (TSA). It is a substrate of HRP enzyme and is used to amplify immunohistochemical signals and in situ hybridization protocols. The compound works through HRP-catalyzed deposition of tyramide conjugates on a solid phase. Biotinyl tyramide dramatically increases AR immunoreactivity in the rat brain. It is used in detecting procalcitonin to distinguish bacterial infections. All applications are limited to non-human research use.
|
| Molecular Formula |
C18H25N3O3S
|
|---|---|
| Molecular Weight |
363.4744
|
| Exact Mass |
363.162
|
| CAS # |
41994-02-9
|
| PubChem CID |
21826423
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.825
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
25
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)NCCC3=CC=C(C=C3)O)NC(=O)N2
|
| InChi Key |
VZWXNOBHWODXCW-ZOBUZTSGSA-N
|
| InChi Code |
InChI=1S/C18H25N3O3S/c22-13-7-5-12(6-8-13)9-10-19-16(23)4-2-1-3-15-17-14(11-25-15)20-18(24)21-17/h5-8,14-15,17,22H,1-4,9-11H2,(H,19,23)(H2,20,21,24)/t14-,15-,17-/m0/s1
|
| Chemical Name |
5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[2-(4-hydroxyphenyl)ethyl]pentanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~275.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7513 mL | 13.7563 mL | 27.5126 mL | |
| 5 mM | 0.5503 mL | 2.7513 mL | 5.5025 mL | |
| 10 mM | 0.2751 mL | 1.3756 mL | 2.7513 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
